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Abstract
Intracellular protein delivery has potential biotechnological and therapeutic application, but 
remains technically challenging. In contrast, a plethora of nucleic acid carriers have been 
developed, with lipid-based nanoparticles (LNPs) among the most clinically advanced reagents for 
oligonucleotide delivery. Here, we validate the hypothesis that oligonucleotides can serve as 
packaging materials to facilitate protein entrapment within and intracellular delivery by LNPs. 
Using two distinct model proteins, horseradish peroxidase and NeutrAvidin, we demonstrate that 
LNPs can yield efficient intracellular protein delivery in vitro when one or more oligonucleotides 
have been conjugated to the protein cargo. Moreover, in experiments with NeutrAvidin in vivo, we 
show that oligonucleotide conjugation significantly enhances LNP-mediated protein uptake within 
various spleen cell populations, suggesting that this approach may be particularly suitable for 
improved delivery of protein-based vaccines to antigen-presenting cells.
1. Introduction
Protein therapeutics comprise a major class of pharmaceuticals, including enzyme 
replacement, monoclonal antibodies, hormones, and protein-based vaccines[1]; however, 
most protein therapeutics act extracellularly, at the cell surface, or if endocytosed, carry out 
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their function within lysosomes. Effective intracellular protein delivery remains a 
challenge[2, 3], yet offers the potential to broaden the scope of diseases amenable to this 
class of drugs and circumvent the inherent risks of gene therapeutics[4].
Cell-penetrating peptides[5] represent one widely studied approach to achieving intracellular 
protein delivery through covalent or non-covalent attachment of protein transduction 
domains, which include TAT-derived peptides[6–8], arginine-rich peptides[9, 10], penetratin 
peptides[11], and amphiphilic peptide carriers such as Pep-1[12]. A related strategy involves 
fusion of a protein known or engineered to achieve intracellular localization, such as herpes 
simplex virus protein VP22[13, 14], or more recently, a supercharged variant of GFP[15]. 
Limitations with these methods include potential immunogenicity and the lack of protection 
from proteases.[16, 17].
A number of materials have been described for nanoparticulate encapsulation and 
intracellular delivery of proteins, including lipids and liposomes[18, 19], charge-
conversional polyionic micelles[20], cationic amphiphiles[21], and various polymers[22–
24]. Nonetheless, because protein loading depends on the strength of non-covalent 
interactions between the protein cargo and the material, these techniques may be useful only 
for a limited subset of proteins with suitable physicochemical properties. An alternative 
approach involves synthesis of a biodegradable polymeric shell directly from the protein 
itself, so that the protein core is encapsulated within a nanocarrier that facilitates 
intracellular delivery[25]. In general, these materials have not yet achieved clinical or even 
preclinical demonstration of their safety and efficacy for systemic delivery.
By comparison, a much wider array of materials has been explored for intracellular delivery 
of nucleic acids[26]. One example includes a group of lipid-like molecules termed lipidoids, 
which demonstrated potent delivery of RNAi therapeutics in preclinical studies involving 
mice, rats, and nonhuman primates[27–29]. We hypothesized that oligonucleotides could 
serve as packaging materials to facilitate protein entrapment within and intracellular delivery 
by these lipid-based nanoparticles (LNPs) (Figure 1a). In this report, we investigate this 
hypothesis by attempting to demonstrate effective LNP-mediated intracellular delivery of 
two model proteins, horseradish peroxidase (HRP) and NeutrAvidin (nAv).
2. Materials and Methods
2.1. Materials
Lipidoids were synthesized as previously described[27]. Horseradish peroxidase (type VI, 
250–330 units/mg), copper (II) sulfate, tris(2-carboxyethyl)phosphine hydrochloride 
(TCEP), tris[(1-benzyl-1H-1,2,3-triazol-4-yl)methyl]amine (TBTA), cholesterol, and O-
phenylenediamine were purchased from Sigma-Aldrich (St. Louis, MO, USA). Unlabeled 
NeutrAvidin, Oregon Green 488-labeled NeutrAvidin, and AlexaFluor 488 carboxylic acid, 
succinimidyl ester, were purchased from Life Technologies (Grand Island, NY, USA). Cy5.5 
mono-reactive NHS ester was acquired from GE Healthcare (Pittsburgh, PA, USA). Three 
oligonucleotide variants (unmodified, 5’-hexynyl, and 5’-biotin-PEG4-modified) with the 
following sequence were custom synthesized and desalted by Integrated DNA Technologies 
(Coralville, IA, USA): 5’-
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CGGGCGCGACTAGTGTGAAATCTGAATAATTTTGTGTTACTC-3’. NHS-PEG4-Azide 
crosslinker, Slide-A-Lyzer G2 dialysis cassettes (20K MWCO), and Zeba Spin desalting 
columns (40K MWCO) were acquired from Pierce Biotechnology (Rockford, IL). 
mPEG2000-DMG was synthesized by Alnylam (Cambridge, MA, USA) as described[30]. 
1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC) and 1,2-dioleoyl-sn-glycero-3-
phosphoethanolamine (DOPE) were obtained from Avanti Polar Lipids (Alabaster, AL, 
USA). HeLa cells (ATCC, Manassas, VA, USA) were cultured in DMEM (Invitrogen) 
supplemented with 10% fetal bovine serum (Invitrogen). Filamentous actin (F-actin) specific 
probe Alexa Fluor® 555 Phalloidin and Prolong gold anti-fade mounting medium were 
purchased from Life Technologies. Alexa Fluor® 647-AffiniPure Rabbit Anti-Horseradish 
Peroxidase antibody was obtained from Jackson ImmunoResearch (West Grove, PA, USA).
2.2. Protein-oligonucleotide conjugation
For DNA oligonucleotide conjugation to horseradish peroxidase (HRP), HRP was first 
azide-functionalized using NHS-PEG4-Azide crosslinker according to the manufacturer’s 
directions. Briefly, NHS-PEG4-Azide (2.27 mM, MW = 388.37 Da) in anhydrous DMSO 
was added to HRP (0.176 mM, MW = 44 kDa) in a total volume of 2.425 mL PBS (20 mM 
sodium phosphate, 0.15 M sodium chloride, pH 7.2) and then incubated for 30 min at RT. To 
quench the reaction, 1 M Tris-HCl (pH 8.0) was added to achieve a final Tris-HCl 
concentration of 0.1 M. The reaction was incubated for an additional 5 min at RT and then 
dialyzed against 3 L PBS overnight at 4°C using a Slide-A-Lyzer G2 cassette (20 K 
MWCO) with two buffer exchanges. Azide-functionalized HRP (72.5 µM) was then 
incubated with 5’-alkyne-modified oligonucleotide (109 µM, MW = 13.14 kDa), CuSO4 (1 
mM), TCEP (4 mM), and TBTA (100 µM) in a final volume of 3.9 mL for 5 h at RT, with 
minor modification from a previous report[31]. The reaction was then purified by dialysis 
against 3 L PBS overnight at 4°C using a Slide-A-Lyzer G2 cassette (20 K MWCO) with 
two buffer exchanges. The HRP-oligo conjugate concentration was determined in two ways 
with roughly equivalent results: absorbance measurement at 403 nm (εHRP, 403 nm = 102 
mM−1 cm−1) using a NanoDrop 1000 spectrophotometer (Thermo Scientific, Waltham, MA, 
USA), and a BCA Protein assay (Thermo Scientific).
For oligo conjugation to NeutrAvidin (nAv), 5’-biotin-PEG4-functionalized oligo (37.2 µM, 
MW = 13.46 kDa) was incubated with fluorescently labeled nAv (18.6 µM, MW = 60 kDa) 
in a final volume of 0.75 ml PBS for 1 h at RT and used without purification. nAv was pre-
labeled with either Cy5.5 mono-reactive NHS ester (GE Healthcare) or AF 488 carboxylic 
acid, succinimidyl ester, (Life Technologies) using the manufacturers’ instructions and was 
purified prior to conjugation using a Zeba Spin desalting column (40 K MWCO) 
equilibrated with PBS. For both labeling reactions, the final fluorophore:protein labeling 
molar ratio was approximately 1:1 as determined with a spectrophotometer. The conjugate 
concentration was determined by using the absorbance measurement at 280 nm 
(εnAv, 280 nm= 99.6 mM−1 cm−1).
2.3. Microfluidic device formulation of lipid nanoparticles (LNPs)
Stock solutions of lipidoid, cholesterol (MW = 387 Da), DSPC (MW = 790 Da), and 
mPEG2000-DMG (MW = 2660 Da) were prepared in ethanol at concentrations of 100, 20, 
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20, and 20 mg/mL, respectively. In most experiments, the components were combined to 
yield molar fractions of 50⋮38.5:10⋮1.5; however, in one experiment, DSPC was substituted 
with DOPE (MW =744 Da) at the same molar fraction.
The HRP-DNA conjugate, or the free HRP control, was diluted in 10 mM citrate buffer (pH 
3.0) at a concentration of 0.5 mg/mL DNA, corresponding to an HRP concentration of 1.13 
mg/mL. Due to differences in stabilities between the free nAv protein and the nAv-DNA 
conjugate, the nAv-DNA conjugate was diluted in 25 mM citrate buffer (pH 5.2) at a 
concentration of 0.375 mg/mL DNA (equivalent protein concentration of 0.845 mg/mL), 
while the free nAv was diluted to 0.845 mg/mL in 10 mM citrate buffer (pH 3.0). The lipid 
solution was diluted as necessary to yield a lipidoid:DNA weight ratio of 10:1.
Microfluidic devices were fabricated as described previously[32]. To prepare LNPs, the 
protein solution and the lipid solution were injected into the microfluidic device at a relative 
volumetric flow rate of 3:1 (0.9 mL/min : 0.3 mL/min) using two syringes (Gastight 
syringes, Hamilton Company, NV, USA) that were controlled by two syringe pumps (PHD 
2000, Harvard Apparatus, MA, USA). To remove ethanol, the freshly prepared LNPs were 
dialyzed for 2 h against 3 L PBS using Slide-A-Lyzer G2 cassettes (20K MWCO).
2.4. Gel electrophoresis
Oligos and protein-oligo conjugates were run on a pre-cast 4–20% polyacrylamide-TBE gel 
(Bio-Rad, Hercules, CA, USA) for 1 h at 100 V. The gel was then stained for 30 min with 
SYBR Gold (Invitrogen) and visualized with a Bio-Rad GelDoc XR+ imager.
LNPs formulated with nAv or nAv-oligo conjugates were run on a pre-cast Any kD mini-
Protean TGX gel (Bio-Rad) for 30 min at 100 V. The gel was stained for 1 h with Bio-Safe 
Coomassie Stain (Bio-Rad), destained overnight, and visualized using a Bio-Rad GelDoc 
XR+ imager. The entrapment efficiency was determined as: (Sfree − SLNP)/Sfree, where Sfree 
is the total signal per lane for the free protein or conjugate and SLNP that for the LNP-
encapsulated protein or conjugate.
2.5. In vitro protein uptake experiments
One day before nanoparticle treatment, HeLa cells (100 µL) were seeded in a clear 96-well 
tissue culture plate at 15,000 cells per well. LNPs and naked protein/conjugate control 
treatments were diluted in freshly warmed growth medium as necessary to achieve the 
indicated protein dose (generally 100 ng − 1 µg per 150 µL per well). The conditioned 
medium was aspirated just before treatment and replaced with the LNPs/proteins diluted in 
fresh medium. The nanoparticles were incubated with cells for 3 h at 37°C.
2.6. HRP activity assay
After incubation with the nanoparticles, the HeLa cells were washed 3 times with PBS (200 
µL) and treated with 0.25% w/v trypsin-EDTA (25 µL) for 5 min at 37°C to detach cells as 
well as to digest any remaining membrane-bound HRP. Upon addition of growth medium 
(50 µL), the cells were pipet-mixed, transferred to a clear 96-well assay plate, pelleted using 
a centrifuge, re-suspended in 100 µL of substrate solution, and repeatedly pipet-mixed. 
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Substrate solution was prepared by dissolving a 15 mg tablet of o-phenylenediamine (OPD) 
in 12.5 mL 100 mM sodium citrate, pH 4.5, and adding 3.5 µL of hydrogen peroxide 
solution (30% w/v) immediately before use. The assay plate was incubated for 10 min at RT 
with orbital shaking prior to addition of 50 µL 2.5 M H2SO4. The absorbance at 490 nm was 
then immediately measured using a SpectraMax 190 microplate reader (Molecular Devices, 
Sunnyvale, CA, USA). The activity assay was performed in an analogous manner on a series 
of dilutions of the free HRP protein and the conjugate to generate a standard curve for each.
2.7. FACS analysis
After aspirating conditioned medium and washing cells three times with PBS, cells were 
detached using 25 µl per well of 0.25% trypsin-EDTA (Invitrogen). Following a 5 min 
incubation at 37°C, fresh medium (50 µl) was added to the cells, which were mixed 
thoroughly and then transferred to a 96-well round-bottom plate. Cells were then pelleted, 
re-suspended in fixation buffer (4% v/v formaldehyde in PBS), incubated for 10 min at RT, 
pelleted again, and finally re-suspended in ice-cold FACS running buffer (2% v/v FBS in 
PBS). The cells were kept at 4°C until FACS analysis using a BD LSR II (Becton Dickinson, 
San Jose, CA, USA). Gating and analysis were performed using FlowJo v8.8 software 
(TreeStar, Ashland, OR, USA).
2.8. HRP immunocytochemistry
HeLa cells were treated on glass cover slips in 6-well plates for 3 h with an LNP dose 
corresponding to 10 µg of HRP per well. The cells were washed 3 times with PBS and then 
fixed using a 4% paraformaldehyde solution at room temperature for 30 min. The cells were 
then washed twice with PBS, permeablized for 30 min using a 0.1% Triton X100 solution, 
and subsequently blocked for 1 h using a 5% normal goat serum solution. Next, the cells 
were incubated for 1 h in an immunostaining cocktail solution consisting of DAPI (3 µM), 
Alexa Fluor® 555 Phalloidin (1:200 dilution), Alexa Fluor® 647-AffiniPure Rabbit Anti-
Horseradish Peroxidase antibody (1:100 dilution), and 5% normal goat serum. After 
staining, the cover slips were washed three times with a 0.1% Tween 20 solution and 
mounted using Prolong gold anti-fade. Immunostained cells were imaged using an LSM 700 
point scanning confocal microscope (Carl Zeiss Microscopy, Jena Germany) equipped with 
a 40 × oil immersion objective. Obtained images were adjusted linearly for presentation 
using Photoshop (Adobe Inc. Seattle, WA).
2.9. Animal experiments
Animal experiments were performed using 6–8 wk old, female C57BL/6 mice (Charles 
River, Wilmington, MA) in accordance with protocols approved by MIT’s Committee on 
Animal Care (CAC). Mice were injected intravenously via the tail-vein with 0.2 mL of LNP 
formulations, unformulated controls, or PBS at a nAv protein dose of 2.5 mg/kg. After 2 h, 
the animals were euthanized, and the livers, spleens, kidneys, lungs and heart were dissected 
and analyzed for fluorescence (ex = 675 nm, em = 720 nm) using an IVIS imaging system 
(Xenogen, Alameda, CA). Xenogen Living Image v. 4.2 acquisition and analysis software 
was used to quantify fluorescent radiant efficiency of each organ from the optical images. 
Spleens were snap frozen on dry ice and freshly embedded in optimal cutting temperature 
compound (OCT). Cryostat sections were cut and collected on superfrost plus treated slides. 
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Prepared frozen sections were kept at −20 °C until needed. The livers and spleens were then 
frozen on dry ice using Tissue-Tek OCT (Sakura, Torrance, CA, USA) and sectioned with a 
cryotome. In accordance with a previously developed method[33], some frozen sections 
were thawed at room temperature for 30 min and then scanned for Cy5.5 fluorescence 
intensity using a Li-COR Odyssey fluorescence scanner (Lincoln, NE, USA) at a resolution 
of 21 µm.
The other frozen sections were fixed using a 4% paraformaldehyde solution at room 
temperature for 30 min. The cryosections were then washed twice with PBS, permeablized 
for 30 min using a 0.1% Triton X100 solution, and subsequently blocked for 1 h using a 5% 
normal goat serum solution. Next, the sections were incubated for 1 h in an immunostaining 
cocktail solution consisting of DAPI (3 µM), Alexa Fluor® 555 Phalloidin (1:200 dilution), 
and 5% normal goat serum. After staining slides were washed three times with a 0.1% 
Tween 20 solution and mounted using Prolong gold anti-fade. Immunostained sections were 
imaged using an LSM 700 point scanning confocal microscope (Carl Zeiss Microscopy, Jena 
Germany) equipped with a 40 × oil immersion objective. Obtained images were adjusted 
linearly for presentation using Photoshop (Adobe Inc. Seattle, WA).
For analysis of splenocyte uptake, spleens were harvested 2 h post-injection, and the spleen 
cell suspension was analyzed for different immune cell populations and for AF488-labeled 
nAv uptake by flow cytometry (CD11b+: cells of the macrophage/monocyte lineage; CD11b
+GR1+: neutrophils; CD11c+: dendritic cells; GR1+: granulocytes; CD19+: B-cells; TCRb
+: T cells).
2.10. Statistics
Data are expressed as mean ± S.D. for groups of at least 3 replicates. Data were analyzed for 
statistical significance by one-way ANOVA with Bonferroni multiple comparison correction, 
as implemented in GraphPad Prism 5 (*: p < 0.05, **: p < 0.01, and ***: p < 0.001).
3. Results and discussion
To develop lipid-based nanoparticles (LNPs) delivery of protein-oligonucleotide conjugates, 
horseradish peroxidase (HRP), a 44 kDa enzyme with an isoelectric point of approximately 
8.0–9.0, was selected as a model protein for delivery. We prepared HRP-oligonucleotide 
conjugates via an azide-alkyne click reaction. Briefly, HRP was azide-functionalized using 
an NHS-ester crosslinker with a short PEG spacer. The azide-modified HRP was then 
conjugated to a 42 base 5’-hexynyl-functionalized DNA oligonucleotide (oligo) with 
reaction conditions as reported previously[31] using a molar ratio of 1.5:1.0 oligo:HRP. A 
gel shift assay confirmed the synthesis of HRP conjugates bearing one or more DNA 
oligonucleotides (Figure 1b).
We first screened a panel of lipidoid formulations for in vitro delivery of the HRP-DNA 
conjugates. Sixteen lipidoids varying in their amine cores and alkyl tails as described[27] 
were mixed with DSPC, mPEG2000-DMG, and cholesterol and then formulated with HRP-
oligonucleotide conjugates. The resulting nanoparticle formulations were incubated with 
HeLa cells for 3 h, after which the cells were washed 3 times with PBS and treated with 
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trypsin to digest any remaining membrane-bound HRP. Subsequently, the cells were 
transferred to an assay plate, pelleted, and re-suspended in OPD substrate buffer for an HRP 
activity assay. As shown in Figure 1c, lipidoids bearing longer alkyl tails (C14) generally 
displayed more effective delivery of active HRP-DNA conjugates. Using the top four 
lipidoids from this screen, further optimization of formulation conditions indicated that 
formulations including DSPC and cholesterol delivered HRP conjugates more effectively 
than those containing DOPE (Figure 1d). In particular, the lipidoid C14-113 (Figure 2) 
outperformed the other lipidoids with respect to delivery activity.
Having identified an LNP formulation mediating delivery of HRP-DNA conjugates, we then 
tested whether effective delivery depends on oligonucleotide conjugation. C14-113 LNPs 
were formulated in one of three ways: with HRP protein alone; with a mixture of HRP 
protein and free, unconjugated oligonucleotide; or with the HRP-oligonucleotide conjugates 
prepared by click chemistry. In addition to naked HRP protein and naked HRP-DNA 
conjugates as control treatments, the formulations were incubated for 3 h with HeLa cells. 
As seen in Figure 3a, only the C14-113 LNPs formulated with HRP-DNA conjugates 
yielded significant HRP activity after washing and trypsinizing the cells. This result suggests 
that HRP-oligonucleotide conjugation is required to achieve effective intracellular HRP 
delivery with these LNPs.
To confirm that the HRP-oligonucleotide conjugates localized within the cells, we 
performed immunocytochemistry (ICC) and confocal microscopy (Figure 3b, Figure S1). 
The imaging data revealed substantial intracellular HRP staining within cells treated with 
LNPs containing HRP-DNA conjugates, but no such staining in cells treated with naked 
HRP-DNA conjugates (Figure S1). These data substantiate the conclusions from the 
enzymatic activity assay that the C14-113 LNPs mediate intracellular uptake of horseradish 
peroxidase-oligonucleotide conjugates.
The same principle was illustrated for intracellular delivery of another model protein, 
NeutrAvidin (nAv), a deglycosylated variant of avidin with a molecular weight of 60 kDa 
and an isoelectric point of 6.3. Fluorescently labeled nAv-oligonucleotide conjugates were 
prepared by incubating Oregon Green 488-labeled nAv, which has four biotin binding sites, 
with various stoichiometric ratios of 5’-biotinylated oligonucleotides. The resulting 
conjugates were analyzed with a gel shift assay, which showed efficient conjugation at the 
1:1 and 2:1 molar ratios of oligo:nAv (Figure 4a). Excess free oligo was detected in the 
mixture prepared at a 4:1 oligo:nAv ratio, most likely due to interference of the fluorescent 
label with one or more of nAv’s four potential biotin-binding sites. For ensuing experiments, 
the oligo:nAv molar ratio was maintained at 2:1.
To determine whether oligonucleotide conjugation affected the encapsulation efficiency of 
nAv within LNPs, C14-113 LNPs were formulated either with free nAv or with nAv-DNA 
conjugates and characterized by SDS-PAGE, alongside naked nAv and naked nAv-DNA 
conjugates (Figure 4b). Quantification of the gel results indicated that the encapsulation 
efficiency of nAv alone within C14-113 LNPs was ~11.0%, in comparison with ~30.8% for 
nAv-DNA conjugates (Table 1). These data suggest that oligonucleotide conjugation 
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enhances the encapsulation efficiency of nAv within C14-113 LNPs approximately 
threefold.
To characterize the effect of oligo conjugation on intracellular nAv delivery in vitro, HeLa 
cells were incubated with one of three C14-113 LNP formulations: those encapsulating nAv 
protein alone, those encapsulating a mixture of nAv protein and unconjugated, unmodified 
DNA oligos; and those encapsulating the nAv-DNA conjugates. HeLa cells were treated for 
3 h with these formulations, along with the naked protein and the naked conjugate 
treatments. The cells were then washed several times, trypsinized, and analyzed by 
fluorescence-activating cell sorting (FACS) for Oregon Green 488 signal. As displayed in 
Figure 4c, neither the naked nAv nor the naked nAv-DNA conjugates yielded significant 
cellular internalization. At the same nAv dose, the C14-113 LNPs encapsulating nAv-DNA 
conjugates achieved uptake in ~65% of HeLa cells, in comparison with ~19% uptake 
efficiency for LNPs encapsulating the nAv protein alone, and ~5% uptake efficiency for 
LNPs encapsulating a mixture of nAv and unconjugated oligo. These results demonstrate 
that oligo conjugation improves intracellular delivery of nAv mediated by C14-113 LNPs. 
Meanwhile, the reduction in uptake observed for LNPs formulated with a mixture of nAv 
and unconjugated oligo compared with those formulated with nAv alone suggests that the 
unconjugated oligo may compete with nAv for loading into the C14-113 LNPs. The extent 
of protein uptake for these treatments was also evaluated by fluorescence microscopy, which 
confirmed that only the HeLa cells treated with C14-113 LNPs encapsulating nAv-DNA 
conjugates showed significant uptake (Figure 4d).
To examine whether oligo conjugation also affects LNP-mediated protein uptake in vivo, we 
investigated the biodistribution of these LNPs 2 h after intravenous (IV) administration to 
mice. As shown by fluorescence imaging of the dissected organs, both the LNPs 
encapsulating the nAv-DNA conjugates (LNP + nAv-DNA) and the LNPs encapsulating the 
free nAv protein (LNP + nAv) were associated with greatly increased nAv-associated Cy5.5 
signal in the liver as compared with naked nAv-oligo conjugates (Figure S2). However, the 
C14-113/nAv-DNA LNP-treated mice showed higher Cy5.5 signal within the spleens and 
lower signal within the kidneys than those that were treated with C14-113/nAv LNPs, 
suggesting altered biodistribution of the protein as a result of protein-oligo conjugation.
To quantify the difference in protein localization observed in the spleens, we imaged the 
organ sections using a Li-COR Odyssey near-infrared fluorescence scanner (Figure 5a). The 
results indicated approximately 2.5-fold higher uptake of nAv in the spleens of mice treated 
with LNPs encapsulating the nAv-oligo conjugates compared with those treated with LNPs 
containing the nAv protein alone (Figure 5b). Furthermore, comparing treatment with 
C14-113/nAv-DNA LNPs and treatment with naked nAv-DNA conjugates, encapsulation 
within LNPs increased spleen protein uptake approximately 3.5-fold. Immunohistochemical 
staining and confocal microscopy of spleen sections confirmed increased accumulation of 
Cy5.5-labeled nAv in those mice treated with C14-113/nAv-DNA LNPs (Figure 6a). By 
comparison, much less accumulation was observed for those mice treated with either naked 
nAv-DNA conjugates or with C14-113/nAv LNPs.
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To determine more quantitatively which immune cell populations within the spleen were 
positive for protein uptake, mice were injected IV with LNPs encapsulating Alexa Fluor 488 
(AF488)-labeled nAv protein or nAv-oligo conjugates, along with their naked counterparts. 
Two hours after injection, the spleens were harvested and the spleen cell suspension was 
analyzed by FACS for various immune cell markers as well as for AF488-labeled nAv 
uptake. Relative to naked nAv or nAv-DNA conjugates, both LNP treatments showed 
increased nAv uptake efficiency in dendritic cells (CD11c+) and cells of the macrophage/
monocyte lineage (CD11b+) (Figure S3). Interestingly, comparing the two LNP treatments, 
the FACS data showed only modestly higher or equivalent nAv uptake efficiency within 
dendritic cells or macrophages/monocytes for the LNPs encapsulating nAv-oligo conjugates. 
For example, the C14-113/nAv-DNA LNPs yielded uptake of nAv in ~37% of splenic 
dendritic cells, compared with ~29% uptake efficiency for C14-113/nAv LNPs. While this 
difference was small but significant (p < 0.001), analysis of the AF488 geometric mean 
fluorescent intensity (MFI) of nAv+ macrophages/monocytes and dendritic cells indicated a 
substantial 2-to-3-fold enhancement in nAv uptake for the LNPs encapsulating the nAv-oligo 
conjugates (Figure 6b). This enhancement is noteworthy considering that there were no 
major differences in the uptake levels of nAv+ macrophage/monocyte cells or dendritic cells 
among the naked control treatment groups and the group treated with LNPs encapsulating 
free nAv. These results indicate that protein-oligo conjugation increases the level of protein 
uptake in those immune cells within the spleen susceptible to intracellular delivery by LNPs.
Recombinant protein-based vaccines are considered less toxic and easier to produce than 
traditional vaccines based on whole organisms; however, the comparatively lower 
immunogenicity of protein-based vaccines requires the development of methods for 
improved delivery to and activation of antigen-presenting cells including dendritic cells and 
macrophages[34, 35]. In this regard, our observation that oligonucleotide conjugation results 
in enhanced LNP-mediated protein uptake within splenic dendritic cells and macrophage/
monocytes may indicate potential utility in the generation of vaccine responses to proteins. 
Further experimentation is necessary to determine whether this enhanced protein uptake is 
also associated with the induction of a more robust immune response characterized by 
increases in relevant cytokine levels and stimulation of specific T-cell and B-cell responses. 
Because immunostimulatory oligos such as those enriched in unmethylated CpG motifs are 
known to be vaccine adjuvants[36–38], the approach outlined here may be suited for the 
delivery of a vaccine comprising a protein antigen conjugated to a functional, 
immunostimulatory oligo adjuvant[39, 40]. These delivery studies with HRP and nAv 
suggest the potential for the use of this oligonucleotide conjugation approach for LNP-
mediated delivery of other protein cargo.
4. Conclusion
Using two distinct model proteins, we demonstrated that intracellular protein delivery with 
lipid-based nanoparticles is dramatically enhanced through conjugation of oligonucleotides 
to the protein cargo. Using click chemistry, we synthesized conjugates of horseradish 
peroxidase (HRP) and a DNA oligonucleotide, and we show that one particular lipidoid, 
C14-113, mediates effective intracellular delivery to HeLa cells of HRP-oligo conjugates but 
not free HRP protein. Similarly, with NeutrAvidin (nAv), a variant of avidin, we show that 
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binding to a biotinylated oligo significantly enhances intracellular nAv delivery by C14-113 
in HeLa cells. When mice were injected intravenously with C14-113 LNPs encapsulating 
either free nAv or nAv-oligo conjugates, we observed that oligonucleotide conjugation 
significantly improved intracellular nAv uptake in macrophage/monocytes and dendritic 
cells within the spleen. These in vivo results suggest that this approach may be suitable for 
enhanced delivery of protein-based vaccines.
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Figure 1. 
(a) Schematic illustrating the use of oligonucleotides (oligos) as packaging materials to 
enhance encapsulation within lipid-based nanoparticles (LNPs). (b) Polyacrylamide gel 
electrophoresis (PAGE) of free DNA oligos and HRP-DNA oligo conjugates. (c) Screening 
of various cationic lipidoids for the intracellular delivery of active HRP-DNA conjugates to 
HeLa cells. An OPD assay was used to measure HRP activity (mean ± SD, n = 4) following 
a 3 h incubation of the LNPs (250 ng HRP/well). ** indicates p <0.01, *** indicates p < 
0.001, compared to naked HRP-DNA control treatment. (d) Optimization of formulation 
composition to achieve effective intracellular HRP delivery (mean ± SD, n = 4) to HeLa 
cells using various cationic lipidoids. ** indicates p <0.01, *** indicates p < 0.001, 
compared to non-treated control.
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Figure 2. 
Structure of C14-113 lipidoid.
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Figure 3. 
(a) Protein-oligonucleotide conjugation is required for effective intracellular delivery of 
HRP by C14-113 LNPs. HeLa cells were treated as indicated for 3 h (500 ng HRP/well) and 
then subjected to an HRP activity assay (mean ± SD, n = 4). *** indicates p < 0.001 
comparing LNP + HRP-DNA treatment to all other control treatments. (b) Following 
treatment of HeLa cells with C14-113 LNPs encapsulating HRP-oligo conjugates, 
immunocytochemical staining and confocal fluorescence microscopy confirmed intracellular 
HRP localization. Cells were treated in 6-well plates for 3 h with an LNP dose 
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corresponding to 10 µg of HRP per well. Blue: nuclei; green: membrane; purple: F-actin; 
red: HRP.
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Figure 4. 
(a) Polyacrylamide gel electrophoresis (PAGE) of free (F) DNA oligos and NeutrAvidin-
DNA oligo conjugates prepared at various molar ratios of oligo:DNA (1:1, 2:1, and 4:1). (b) 
SDS-PAGE of naked nAv protein (P), naked nAv-oligo conjugate (C), C14-113 LNPs 
encapsulating nAv protein (LP), and C14-113 LNPs encapsulating nAv-oligo conjugates 
(LC). (c) Protein-oligonucleotide conjugation is required for efficient intracellular delivery 
of nAv by C14-113 LNPs. HeLa cells were treated as indicated for 3 h (100 ng Oregon 
Green 488-labeled nAv/well), and the uptake efficiency was assessed by FACS analysis 
(mean ± SD, n = 4). *** indicates p < 0.001 comparing LNP + nAv-DNA treatment to all 
other control treatments. (d) Fluorescence microscopy images of HeLa cells treated for 3 h 
with the indicated Cy5.5-labeled nAv formulations (250 ng nAv/well).
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Figure 5. 
(a) Near-infrared fluorescence scans of Cy5.5 signal in spleen sections harvested from mice 
2 h after IV injection of the indicated Cy5.5-labeled nAv treatments. (b) Quantification of 
mean gray values of spleens for each group (n = 3). *** indicates p < 0.001 comparing LNP 
+ nAv-DNA treatment to all other control treatments.
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Figure 6. 
(a) Immunohistochemical staining revealed accumulation of Cy5.5-labeled nAv in spleen 
sections harvested from mice 2 h after IV injection of C14-113 / nAv-DNA LNPs. (b) Mice 
were injected IV with the indicated AF488-labeled nAv treatments, and the spleens were 
harvested 2 h post-injection. The spleen cell suspension was analyzed by FACS for different 
immune cell populations as well as for the geometric mean fluorescent intensity (MFI) of 
positive (AF488+) cells. CD11b+: cells of the macrophage/monocyte lineage; CD11b
+GR1+: neutrophils; CD11c+: dendritic cells; GR1+: granulocytes; CD19+: B-cells; TCRb
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+: T cells. ** indicates p <0.01, *** indicates p < 0.001, comparing LNP + nAV-DNA group 
to LNP + nAv group.
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Table 1
Biophysical characterization of LNPs formulated with nAv or nAv-DNA conjugates
Encapsulation
Efficiency (%)
Size (nm) PDI ζ-potential (mV)
LNP + nAv 11.0 79.4 ± 1.9 0.115 +0.18
LNP + nAv-DNA 30.8 234.3 ± 13.4 0.151 +0.65
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